Apicore data files DMF for Fondaparinux Sodium API with U.

.. Apicore data files DMF for Fondaparinux Sodium API with U.S. FDA Apicore LLC announced today that they filed a medication master file for Fondaparinux Sodium dynamic pharmaceutical ingredient with the U.S. Food and Drug Administration on June 28, 2010. The market for branded item in the usa was $266 million in the 12 weeks ended on March 31, 2010, an increase of 44 percent over the prior year, . The company, established in 2005, evolves and producers APIs at its development laboratories and manufacturing sites situated in Somerset, NJ, Vadodara and India, Gujarat, India for generic pharmaceutical customers worldwide Mr. Ambrose Stafford, Vice President, Apicore LLC said, We’re very proud of the skill and dedication of our team who’ve worked tirelessly over several years to achieve this main milestone of completing the advancement of Fondaparinux Sodium API.BMA Wales said its report, Behind the Smokescreen, would ‘clear the atmosphere’ on the data offered to the AMs sitting on the assembly’s committee, the statement claims evidence shows that passive smoking escalates the risk of lung cancer in non smokers by 20-30 percent and says that proof from Ireland, which brought in a ban this past year, shows that banning smoking in public places will not increase smoking in homes. The effects are said by The report of passive smoking kill 30 people daily.